戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ptor modulators and a modified testosterone (danazol).
2 clinically used drugs like norethindrone and danazol.
3 tenance therapy with the oral combination of danazol (10-15 mg/kg) and azathioprine (2 mg/kg) was giv
4 nazol placebo (ie, the momelotinib group) or danazol (300 mg orally twice per day) plus momelotinib p
5 ts (C1-INH concentrate, tranexamic acid, and danazol) administered for STP.
6                                              Danazol also upregulated the cell cycle inhibitor p21 in
7    Gonadotropin-releasing hormone analogues, danazol, and depot progestagens are associated with a hi
8 ome patients respond to cyclosporine A or to danazol, but most patients do not respond to any therapy
9  results, docking studies have revealed that danazol can likely bind favourably with STAT3.
10  compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadon
11                     Known adverse effects of danazol--elevated liver-enzyme levels and muscle cramps-
12     Taken together, our results suggest that danazol exerts a CS effect by inhibiting the STAT3 pathw
13 attacks and progestins, tranexamic acid, and danazol for the prevention of attacks.
14 otinib group (200 mg orally once per day) or danazol group (300 mg orally twice per day) through week
15 d a 50% or more reduction in TSS than in the danazol group (32 [25%] of 130 vs six [9%] of 65; propor
16  either the momelotinib group (130 [67%]) or danazol group (65 [33%]) and received study treatment in
17  momelotinib group and 41 (63%) of 65 in the danazol group entered the momelotinib open-label extensi
18 ontinued treatment and 15 (50%) of 30 in the danazol group who crossed over were responders.
19 roup who continued and 19 (59%) of 32 in the danazol group who crossed over, including most week 24 r
20 e per day) plus momelotinib placebo (ie, the danazol group), stratified by total symptom score (TSS;
21 in the momelotinib group and 65 [33%] in the danazol group).
22            H(1)-antihistamines, montelukast, danazol, H(2)-antihistamines, pentoxifylline, doxepin, a
23  of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, symptomatic patients w
24 and anaemia benefits with momelotinib versus danazol in patients with myelofibrosis.
25                                              Danazol induced the arrest of MDR cancer cells at the G2
26 g-term benefit, are immunosuppressive drugs, danazol, intravenous immunoglobulin, and plasma exchange
27            When this agent is not available, danazol is a potential alternative for prophylaxis befor
28                 In our study, treatment with danazol led to telomere elongation in patients with telo
29 ated compounds that were tested (stanozolol, danazol, methandrostenolone) modestly stimulated aromata
30 s, we administered the synthetic sex hormone danazol orally at a dose of 800 mg per day for a total o
31 omelotinib (200 mg orally once per day) plus danazol placebo (ie, the momelotinib group) or danazol (
32              Compared with natural hormones, danazol possessed a stronger selective cytotoxicity agai
33            Furthermore, in MDR cancer cells, danazol reduced STAT3 phosphorylation as well as the exp
34    Treatment with momelotinib, compared with danazol, resulted in clinically significant improvements
35 tranexamic acid (four women), and 100% under danazol (three women).
36 a clinically used synthetic steroid hormone, danazol, was investigated for its CS properties and cyto
37 emergent adverse events with momelotinib and danazol were acute kidney injury (four [3%] of 130 vs si
38 emergent adverse events with momelotinib and danazol were haematological abnormalities by laboratory